Sam Osman is an accomplished CEO currently leading Endpoint Clinical and Neovance, with a robust background in technology and life sciences. With a track record of successful product launches and operational turnarounds, they have driven substantial growth for various companies, achieving over $50M growth within 36 months in prior roles. Their extensive experience includes strategic positions at organizations such as Science and Medicine Group and Cenduit, where they turned around the IRT business and facilitated its sale to IQVIA. Sam has also been instrumental in restructuring management teams to enhance performance and has served on the boards of multiple companies in the healthcare sector. They hold advanced degrees from institutions including Carnegie Mellon University and The London School of Economics and Political Science.
This person is not in the org chart
This person is not in any teams
This person is not in any offices